Navigation Links
Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds

renally impaired patients. In addition, taken as convenient once daily or once weekly capsules, the prodrug results in rapid and complete absorption and distribution of isavuconazole to infected tissues.

Basilea successfully completed its phase II trial with both high clinical cures rates and a safety profile comparable to gold standard fluconazole therapy and with a more flexible dosing schedule. Clinical drug interaction studies have illustrated attractive pharmacokinetic features and the potential for less drug-drug interactions than a number of broad-spectrum antifungal drugs in current use. Isavuconazole is in phase III testing with two global primary-treatment phase III trials for the treatment of invasive yeast and mold infections.

About Basilea

Basilea Pharmaceutica Ltd. is an independent biopharmaceutical company headquartered in Basel, Switzerland, and listed on the SWX Swiss Exchange (SWX:BSLN). Basilea's fully integrated research and development operations are currently focused on new antibacterial and antifungal agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio including three investigational phase III drugs of which two have shown positive pivotal phase III results. Basilea is building a sustainable hospital and specialty pharmaceutical business. The company is integrating commercialization into its organization, in a first step through co-promoting ceftobiprole.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially d
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
2. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
6. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
7. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
8. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
9. Inspire Announces Presentations at Two European Scientific Conferences
10. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
11. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
Post Your Comments:
(Date:8/21/2014)... 2014 /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada ... its Board of Directors, enhancing executive oversight and ... a leading licensed producer of medicinal cannabis in ... 13 years, experience in producing and supplying government-regulated ... Canada. As previously announced in ...
(Date:8/21/2014)... (NASDAQ: CYBX ) today announced results for the ... 1   Operating results for the first quarter ... 2014, and other achievements, include: , Worldwide net product ... Strong international net sales of $13.2 million, an increase of ... product sales reached a new high of $58.8 million, an ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
... SANTA MARIA, Calif., Feb. 14, 2011 Hardy Diagnostics, ... the release of HardyCHROM™ SS, a highly selective chromogenic ... for the isolation and differentiation of Salmonella ... two pathogens can be easily distinguished from non-pathogenic enteric ...
... MedQuist Holdings Inc. (Nasdaq: MEDH ), formerly ... documentation solutions for the U.S. healthcare system, today announced ... shares of its common stock.  The shares began trading ... under the ticker symbol MEDH. In ...
Cached Medicine Technology:The Only Chromogenic Medium That Detects Both Salmonella and Shigella! 2MedQuist Holdings Inc. Announces Closing of Its Initial U.S. Public Offering and Acquisition of Additional Shares of MedQuist Inc. 2MedQuist Holdings Inc. Announces Closing of Its Initial U.S. Public Offering and Acquisition of Additional Shares of MedQuist Inc. 3
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
(Date:8/21/2014)... -- Among seniors, dimming vision may be tied to ... than 2,500 people, aged 65 to 84, who were assessed ... and eight years later. Vision loss over time was ... during the study period, the researchers reported. Although the ... Christ of Purdue University in West Lafayette, Ind., offered up ...
(Date:8/21/2014)... A new study published this week ... disability associated with speech problems from 2001-02 to 2010-11 ... increase in disability associated with hearing problems. The data ... of children who are experiencing communication disorders, according to ... On a broader level, the new study, Changing ...
(Date:8/21/2014)... Aug. 21, 2014 Researchers in the United Kingdom ... can quickly and accurately diagnose a number of rare ... study published online today in Ophthalmology , ... Using a single test, doctors were able to tailor ... mutations reducing the time and money spent on diagnosis ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The ... Market by Pollutant Control System (FGD, DeNOx, Particulate ... Iron & Steel, Chemical & Others) - Global ... the global industrial flue gas treatment systems & ... global market size in terms of value. The ...
Breaking Medicine News(10 mins):Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... have found that recognisation of West Nile Virus (WNV) ... allows the virus to cross the blood-brain barrier (BBB) ... stranded RNA (ssRNA) flavivirus with a life cycle that ... can become infected. In humans, infection is generally asymptomatic ...
... a conference of the International Aids Society Conference in// ... men were 65 per cent less likely to become ... studies have suggested that circumcision lowers rate of HIV ... Africa, where some tribes routinely circumcised while others did ...
... Hail protein! So finally scientists have been able to zero ... The basis of the well known “rage” diets like Atkins ... restriction of carbohydrate foods. As a consequence protein in the ... for weight loss and rightly so. These diets work in ...
... may be using baby talks for longer times than ... warns scientists. ,Linda Crowe, associate professor in the ... said that it’s important for the parents to identify ... delays can range from a child being slow to ...
... and other clinically important conditions that would be missed ... according to a study in the August issue of Radiology. ... may be as significant as the chance of finding cancer ... at the Veterans Affairs Medical Center and associate professor and ...
... to conventional// therapy may soon get help from a ... a professor of gastroenterology at the University of Alberta, ... and the University of North Carolina administered probiotic bacteria ... aged 18-65. ,Probiotics are preparations of living ...
Cached Medicine News:Health News:Toll-like Receptor (Tlr3) Attachment Leads To Lethal Encephalitis 2Health News:More News That Circumcision Could Reduce risk of HIV infection 2Health News:Weighty problem: Protein is the solution? 2Health News:Weighty problem: Protein is the solution? 3Health News:Weighty problem: Protein is the solution? 4Health News:Language Delays May Not Be Normal In Children 2Health News:Virtual Colonoscopy May Be Better Than Real-time Colonoscopy 2
Nidek offers 3-Dx Digital stereo camera to provide a complete and comprehensive digital imaging platform....
Measurement of progressive multi-focal lenses is fast and easy with the CLM-3000 auto-lensmeter. The data is represented in a simple to understand bar graphic display....
Auto Lensmeter LM-970...
Autolensmeter with black/white monitor and no internal printer....
Medicine Products: